

梅雪鋒,美國喬治敦大學(xué)(Georgetown University)化學(xué)博士。中國科學(xué)院上海藥物研究所,藥物質(zhì)量控制與固體化學(xué)研究中心主任,研究員,課題組長。2006-2010年間就職于美國新澤西州著名制藥企業(yè)諾華制藥公司(美國),擔(dān)任高級(jí)研究員,項(xiàng)目負(fù)責(zé)人;2010年回國工作,2011年起擔(dān)任藥物質(zhì)量控制與固態(tài)化學(xué)研究中心主任;中國藥物晶體協(xié)會(huì)執(zhí)行委員。主要從事藥物固態(tài)化學(xué)和藥物分析化學(xué)方面的工作,研究內(nèi)容涉及藥物共結(jié)晶的設(shè)計(jì)與合成研究,藥物固態(tài)化學(xué)表征、成鹽和多晶型篩選等方面。
藥物固態(tài)化學(xué),成鹽和多晶型篩選,藥物共結(jié)晶及藥物開發(fā)中的質(zhì)量研究
2008年 獲諾華公司“老虎團(tuán)”成員獎(jiǎng)? ?
2007年 獲諾華公司“超越貢獻(xiàn)”獎(jiǎng)? ?
2006年 獲優(yōu)秀博士畢業(yè)生獎(jiǎng)
2010-2014“中科院引進(jìn)海外杰出人才計(jì)劃” 中國科學(xué)院? ?
2011-2013“微量藥物溶出動(dòng)力學(xué)測試設(shè)備” 中國科學(xué)院??
2011-2015“抗腫瘤藥物早期成藥性評(píng)價(jià)關(guān)鍵技術(shù)研究” 科技部重大專項(xiàng)? ?
2011- 2015“重大新藥創(chuàng)制綜合性大平臺(tái)-藥物質(zhì)量研究平臺(tái)建設(shè)” 科技部重大專項(xiàng)??
2013-2016“重力沉降固相分離方法運(yùn)用于藥物制劑中的晶型分析研究”自然科學(xué)基金? ?
2017-2020“藥物一致性評(píng)價(jià)-藥物晶型研究” 科技部重大專項(xiàng)
1. Wang, J.-R.; Li, M.; Yu, Q.; Zhang, Z.; Zhu, B.; Qin, W.;?Mei, X.* Anisotropic elasticity and plasticity of an organic crystal.?Chem. Commun. 2019, 55, (59), 8532-8535.
2. Li, Z.; Li, M.; Peng, B.; Zhu, B.; Wang, J.-R.;?Mei, X.* Improving Compliance and Decreasing Drug Accumulation of Diethylstilbestrol through Cocrystallization.?Cryst. Growth Des. 2019, 19, (3), 1942-1953.
3. Cheng, L.; Zhu, B.; Ma, X.; Zhang, Z.; Wang, J. R.; Zhang, Q.;?Mei, X.* Identification of an Overlooked Halogen-Bond Synthon and Its Application in Designing Fluorescent Materials.?Chem. Eur. J.?2019, 25, (26), 6584-6590.
4. Zhu, B.; Fang, X.; Zhang, Q.;?Mei, X.* Ren, G., Study of Crystal Structures, Properties, and Form Transformations among a Polymorph, Hydrates, and Solvates of Apatinib.?Cryst. Growth Des. 2019, 19, (5), 3060-3069.
5. Peng, B.; Zhang, Z.; Wang, J. R.; Li, M.; Zhang, Q.;?Mei, X.* Confocal Raman micro-spectral evidence and physicochemical evaluation of triamterene salts.?Analyst?2019, 144, (2), 530-535.
6. Peng, B.; Wang, J.-R.;?Mei, X.* Triamterene-furosemide salt: structural aspects and physicochemical evaluation. Acta Cryst. B 2018, 74, (6), 738-741.
7. Li, M.; Li, Z.; Zhang, Q.; Peng, B.; Zhu, B.; Wang, J.-R.; Liu, L.;?Mei, X.* Fine-Tuning the Colors of Natural Pigment Emodin with Superior Stability through Cocrystal Engineering.?Cryst. Growth Des.?2018, 18, (10), 6123-6132.
8. Wang, F.-Y.; Zhang, Q.; Zhang, Z.; Gong, X.; Wang, J.-R.;?Mei, X.* Solid-state characterization and solubility enhancement of apremilast drug-drug cocrystals.?CrystEngComm?2018, 20, (39), 5945-5948.
9. Zhu, B.; Wang, J.-R.; Zhang, Q.; Li, M.; Guo, C.; Ren, G.;?Mei, X.* Stable Cocrystals and Salts of the Antineoplastic Drug Apatinib with Improved Solubility in Aqueous Solution.?Cryst. Growth Des. 2018, 18, (8), 4701-4714.
10. Zha, J.; Zhang, Q.; Li, M.; Wang, J.-R.;?Mei, X.* Improving Dissolution Properties by Polymers and Surfactants: A Case Study of Celastrol.?J. Pharm. Sci.?2018, 107, (11), 2860-2868.
11. Bao, J.; Zhang, Z.; Yan, Z.; Wang, J.-R.;?Mei, X.* Cocrystallization in vitamin B9 gels to construct stoichiometry-controlled isostructural materials.?CrystEngComm?2018, 20, (12), 1644-1648.
12. He, H.; Zhang, Q.; Wang, J.-R.;?Mei, X.* Structure, physicochemical properties and pharmacokinetics of resveratrol and piperine cocrystals.?CrystEngComm?2017, 19, (41), 6154-6163.
13. Zhu, B.; Zhang, Q.; Ren, G.;?Mei, X.* Solid-State Characterization and Insight into Transformations and Stability of Apatinib Mesylate Solvates.?Cryst. Growth Des. 2017, 17, (11), 5994-6005.
14. Yu, Q.; Yan, Z.; Bao, J.; Wang, J.-R.;?Mei, X.* Taming photo-induced oxidation degradation of dihydropyridine drugs through cocrystallization.?Chem. Commun. 2017, 53, (91), 12266-12269.
15. Li, M. Q.; Zhang, Q.; He, H. Y.; Wang, J.-R.;?Mei, X.* Vapor triggered fluorescent color changes among solvates of Emodin.?J. Mater. Chem. C?2017, 5, (24), 5970-5976.
16. He, H.; Zhang, Q.; Li, M.; Wang, J.-R.; Mei, X.* Modulating the Dissolution and Mechanical Properties of Resveratrol by Cocrystallization.?Cryst. Growth Des. 2017, 17, (7), 3989-3996.
17. Wang, J.-R.; Zhu, B.; Zhang, Z.; Bao, J.; Deng, G.; Ding, Q.;?Mei, X.* Polymorphism of Triamcinolone Acetonide Acetate and Its Implication for the Morphology Stability of the Finished Drug Product.?Cryst. Growth Des. 2017, 17, (6), 3482-3490.
18. Zhu, B.; Zhang, Q.; Wang, J.-R.;?Mei, X.* Cocrystals of Baicalein with Higher Solubility and Enhanced Bioavailability.?Cryst. Growth Des. 2017, 17, (4), 1893-1901.
19. Zhang, Q.; Jia, L.; Wang, J.-R.;?Mei, X.* Absolute asymmetric synthesis of a sanguinarine derivative through crystal-solution interactions.?CrystEngComm?2016, 18, (46), 8834-8837.
20. Wang, J.-R.; Bao, J.; Fan, X.; Dai, W.;?Mei, X.* pH-switchable vitamin B9 gels for stoichiometry-controlled spherical co-crystallization.?Chem. Commun. 2016, 52, (92), 13452-13455.
21. Li, M.; Zhang, Q.; Wang, J. R.;?Mei, X.* Mechanochromism triggered fluorescent color switching among polymorphs of a natural fluorescence pigment.?Chem. Commun. 2016, 52, (75), 11288-11291.
22. Zhu, B.; Wang, J.-R.; Ren, G.;?Mei, X.* Polymorphs and Hydrates of Apatinib Mesylate: Insight into the Crystal Structures, Properties, and Phase Transformations.?Cryst.?Growth Des. 2016, 16, (11), 6537-6546.
23. Zhu, B.; Wang, J.-R.; Zhang, Q.;?Mei, X.* Greener solid-state synthesis: stereo-selective [2 + 2] photodimerization of vitamin K3 controlled by halogen bonding.?CrystEngComm?2016, 18, (34), 6327-6330.
24. Zhang, Q.;?Mei, X.* Two New Polymorphs of Huperzine A Obtained from Different Dehydration Processes of One Monohydrate.?Cryst. Growth Des. 2016, 16, (6), 3535-3542.
25. Wang, J.-R.; Wang, X.; Yang, Y.; Chen, X.;?Mei, X.* Solid-state characterization of 17beta-estradiol co-crystals presenting improved dissolution and bioavailability.?CrystEngComm?2016, 18, (19), 3498-3505.
26. He, H.; Huang, Y.; Zhang, Q.; Wang, J.-R.;?Mei, X.* Zwitterionic Cocrystals of Flavonoids and Proline: Solid-State Characterization, Pharmaceutical Properties, and Pharmacokinetic Performance. Cryst. Growth Des. 2016, 16, (4), 2348-2356.
27. Zhu, B.; Wang, J.-R.; Zhang, Q.;?Mei, X.* Improving Dissolution and Photostability of Vitamin K3 via Cocrystallization with Naphthoic Acids and Sulfamerazine.?Cryst. Growth Des. 2016, 16, (1), 483-492.
28. Wang, J.-R.; Yu, Q.; Dai, W.;?Mei, X.* Drug-drug co-crystallization presents a new opportunity for the development of stable vitamins.?Chem. Commun. 2016, 52, (17), 3572-3575.
29. Wang, J.-R.; Zhu, B.; Yu, Q.;?Mei, X.* Selective crystallization of vitamin D3 for the preparation of novel conformational polymorphs with distinctive chemical stability.?CrystEngComm?2016, 18, (7), 1101-1104.
30. Wang, J.-R.; Zhou, C.; Yu, X.;?Mei, X.* Stabilizing vitamin D3 by conformationally selective co-crystallization.?Chem. Commun. 2014, 50, (7), 855-858.